ES2123477T1 - Composicion biologicamente activa que comprende ciclosporina. - Google Patents
Composicion biologicamente activa que comprende ciclosporina.Info
- Publication number
- ES2123477T1 ES2123477T1 ES96923154T ES96923154T ES2123477T1 ES 2123477 T1 ES2123477 T1 ES 2123477T1 ES 96923154 T ES96923154 T ES 96923154T ES 96923154 T ES96923154 T ES 96923154T ES 2123477 T1 ES2123477 T1 ES 2123477T1
- Authority
- ES
- Spain
- Prior art keywords
- biologically active
- phase
- active composition
- cyclosporine
- specific
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title abstract 4
- 108010036949 Cyclosporine Proteins 0.000 title abstract 4
- 229960001265 ciclosporin Drugs 0.000 title abstract 4
- 229930182912 cyclosporin Natural products 0.000 title abstract 4
- 229930105110 Cyclosporin A Natural products 0.000 title 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 abstract 1
- 229940088623 biologically active substance Drugs 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 229940125721 immunosuppressive agent Drugs 0.000 abstract 1
- 239000003018 immunosuppressive agent Substances 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Transplantation (AREA)
- Dispersion Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Air-Conditioning For Vehicles (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE DESCRIBE UNA COMPOSICION BIOLOGICAMENTE ACTIVA BASADA EN UNA FASE L2 DE UN MONOGLICERIDO ESPECIFICO, UN TRIGLICERIDO ESPECIFICO Y UN LIQUIDO POLAR ESPECIFICO, ESTANDO UNA CICLOSPORINA DISUELTA O DISPERSADA EN DICHA FASE L2 COMO SUSTANCIA BIOLOGICAMENTE ACTIVA. SE DESCRIBE UN PROCEDIMIENTO PARA LA PREPARACION DE DICHA COMPOSICION, EN EL CUAL SE AÑADE LA CICLOSPORINA A LA FASE L2 ANTES, DURANTE O DESPUES DE LA FORMACION DE LA MISMA. SE DESCRIBE EL USO DE DICHA FASE L2 PARA LA ENCAPSULACION DE UNA CICLOSPORINA PARA LA FABRICACION DE UNA PREPARACION PARA LA ADMINISTRACION ORAL PARA SU UTILIZACION COMO AGENTE INMUNOSUPRESOR.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9502472A SE504582C2 (sv) | 1995-07-06 | 1995-07-06 | Cyklosporinkomposition baserad på en L2-fas |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2123477T1 true ES2123477T1 (es) | 1999-01-16 |
| ES2123477T3 ES2123477T3 (es) | 2002-08-01 |
Family
ID=20398887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES96923154T Expired - Lifetime ES2123477T3 (es) | 1995-07-06 | 1996-07-02 | Composicion biologicamente activa que comprende ciclosporina. |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP0873133B1 (es) |
| JP (1) | JPH11508592A (es) |
| AT (1) | ATE213951T1 (es) |
| AU (1) | AU6374596A (es) |
| BR (1) | BR9609332A (es) |
| CA (1) | CA2226219A1 (es) |
| CZ (1) | CZ1998A3 (es) |
| DE (2) | DE873133T1 (es) |
| ES (1) | ES2123477T3 (es) |
| NO (1) | NO980032L (es) |
| SE (1) | SE504582C2 (es) |
| WO (1) | WO1997002042A1 (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE511313C2 (sv) | 1997-01-13 | 1999-09-06 | Gs Dev Ab | Komposition med reglerad frisättning innefattande fettsyraester av diacylglycerol |
| WO1999029316A1 (en) | 1997-12-10 | 1999-06-17 | Severson, Mary, L. | Pharmaceutical compositions containing an omega-3 fatty acid oil |
| US6979456B1 (en) | 1998-04-01 | 2005-12-27 | Jagotec Ag | Anticancer compositions |
| US6638522B1 (en) * | 1998-12-11 | 2003-10-28 | Pharmasolutions, Inc. | Microemulsion concentrate composition of cyclosporin |
| DE60221287D1 (de) | 2001-11-08 | 2007-08-30 | Atrium Medical Corp | Intraluminale vorrichtung mit einer ein therapeutisches-mittel enthaltenden beschichtung |
| US9801982B2 (en) | 2004-09-28 | 2017-10-31 | Atrium Medical Corporation | Implantable barrier device |
| US9000040B2 (en) | 2004-09-28 | 2015-04-07 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
| US8367099B2 (en) | 2004-09-28 | 2013-02-05 | Atrium Medical Corporation | Perforated fatty acid films |
| US9012506B2 (en) | 2004-09-28 | 2015-04-21 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
| EP1811935B1 (en) | 2004-09-28 | 2016-03-30 | Atrium Medical Corporation | Heat cured gel and method of making |
| US9592324B2 (en) | 2006-11-06 | 2017-03-14 | Atrium Medical Corporation | Tissue separating device with reinforced support for anchoring mechanisms |
| US8312836B2 (en) | 2004-09-28 | 2012-11-20 | Atrium Medical Corporation | Method and apparatus for application of a fresh coating on a medical device |
| US20060067977A1 (en) | 2004-09-28 | 2006-03-30 | Atrium Medical Corporation | Pre-dried drug delivery coating for use with a stent |
| US9278161B2 (en) | 2005-09-28 | 2016-03-08 | Atrium Medical Corporation | Tissue-separating fatty acid adhesion barrier |
| US9427423B2 (en) | 2009-03-10 | 2016-08-30 | Atrium Medical Corporation | Fatty-acid based particles |
| AU2006304590A1 (en) | 2005-10-15 | 2007-04-26 | Atrium Medical Corporation | Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings |
| US9492596B2 (en) | 2006-11-06 | 2016-11-15 | Atrium Medical Corporation | Barrier layer with underlying medical device and one or more reinforcing support structures |
| ES2393814T3 (es) | 2007-04-04 | 2012-12-28 | Sigmoid Pharma Limited | Una composición farmacéutica oral |
| ES2530049T3 (es) | 2009-05-18 | 2015-02-26 | Sigmoid Pharma Limited | Composición que comprende gotas de aceite |
| US20110038910A1 (en) | 2009-08-11 | 2011-02-17 | Atrium Medical Corporation | Anti-infective antimicrobial-containing biomaterials |
| CN102573802A (zh) | 2009-08-12 | 2012-07-11 | 希格默伊德药业有限公司 | 包含聚合物基质和油相的免疫调节组合物 |
| US10322213B2 (en) | 2010-07-16 | 2019-06-18 | Atrium Medical Corporation | Compositions and methods for altering the rate of hydrolysis of cured oil-based materials |
| GB201020032D0 (en) | 2010-11-25 | 2011-01-12 | Sigmoid Pharma Ltd | Composition |
| JO3337B1 (ar) * | 2010-12-13 | 2019-03-13 | Debiopharm Sa | تركيبات صيدلية تشمل أليسبوريفير |
| US9867880B2 (en) | 2012-06-13 | 2018-01-16 | Atrium Medical Corporation | Cured oil-hydrogel biomaterial compositions for controlled drug delivery |
| GB201304662D0 (en) | 2013-03-14 | 2013-05-01 | Sigmoid Pharma Ltd | Compositions |
| JP6716582B2 (ja) * | 2014-11-07 | 2020-07-01 | サブリミティ・セラピューティクス・リミテッドＳｕｂｌｉｍｉｔｙ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | シクロスポリンを含む組成物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2907460A1 (de) * | 1978-03-07 | 1979-09-13 | Sandoz Ag | Neue resorbierbare galenische kompositionen |
| SE457693B (sv) * | 1986-07-01 | 1989-01-23 | Drilletten Ab | Komposition med reglerad frigoering vari ett biologiskt material aer loest eller dispergerat i en l2-fas |
| GB9113872D0 (en) * | 1991-06-27 | 1991-08-14 | Sandoz Ag | Improvements in or relating to organic compounds |
-
1995
- 1995-07-06 SE SE9502472A patent/SE504582C2/sv not_active IP Right Cessation
-
1996
- 1996-07-02 EP EP96923154A patent/EP0873133B1/en not_active Expired - Lifetime
- 1996-07-02 CA CA002226219A patent/CA2226219A1/en not_active Abandoned
- 1996-07-02 ES ES96923154T patent/ES2123477T3/es not_active Expired - Lifetime
- 1996-07-02 DE DE0873133T patent/DE873133T1/de active Pending
- 1996-07-02 WO PCT/SE1996/000893 patent/WO1997002042A1/en not_active Ceased
- 1996-07-02 CZ CZ9819A patent/CZ1998A3/cs unknown
- 1996-07-02 BR BR9609332A patent/BR9609332A/pt not_active Application Discontinuation
- 1996-07-02 AU AU63745/96A patent/AU6374596A/en not_active Abandoned
- 1996-07-02 DE DE69619700T patent/DE69619700T2/de not_active Expired - Fee Related
- 1996-07-02 JP JP9505078A patent/JPH11508592A/ja active Pending
- 1996-07-02 AT AT96923154T patent/ATE213951T1/de not_active IP Right Cessation
-
1998
- 1998-01-05 NO NO980032A patent/NO980032L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CZ1998A3 (cs) | 1998-06-17 |
| JPH11508592A (ja) | 1999-07-27 |
| AU6374596A (en) | 1997-02-05 |
| DE873133T1 (de) | 1999-05-06 |
| NO980032L (no) | 1998-03-03 |
| NO980032D0 (no) | 1998-01-05 |
| SE9502472L (sv) | 1997-01-07 |
| CA2226219A1 (en) | 1997-01-23 |
| SE9502472D0 (sv) | 1995-07-06 |
| BR9609332A (pt) | 1999-05-25 |
| EP0873133A1 (en) | 1998-10-28 |
| DE69619700T2 (de) | 2002-10-24 |
| EP0873133B1 (en) | 2002-03-06 |
| ATE213951T1 (de) | 2002-03-15 |
| DE69619700D1 (de) | 2002-04-11 |
| WO1997002042A1 (en) | 1997-01-23 |
| SE504582C2 (sv) | 1997-03-10 |
| ES2123477T3 (es) | 2002-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2123477T1 (es) | Composicion biologicamente activa que comprende ciclosporina. | |
| Stellato et al. | Anti-inflammatory effect of cyclosporin A on human skin mast cells | |
| NZ504076A (en) | A topical formulation which induces a minimal systemic effect when applied to the skin, the topical formulation comprising an immunosuppressive macrolide selected from sirolimus, FK506 and SDZ ASM 981 and a permeation modulator for the treatment of a dermatological condition | |
| ATE333898T1 (de) | Glycerinmonolaurat und laurylacetat enthaltende mittel zur hautpenetrationsbeschleunigung | |
| RU94045136A (ru) | Композиция для ухода за кожей, способ ухода за кожей | |
| EP0983994A3 (de) | Dimethyl-(3-aryl-but-3-enyl)-aminverbindungen als pharmazeutische Wirkstoffe | |
| BR9608785A (pt) | Forma de dosagem oral contendo como um princípio ativo um ácido mega-3- poli insaturado uso de um ácido ómega-3-poli insaturado e processo de tratar inflamação intestinal | |
| KR860002271A (ko) | 조절되게 방출되게끔(controlled-release) 코오팅된 조제학상의 제제와 그 제제의 제조방법 | |
| ES2088160T3 (es) | Formulacion y proceso quimicos. | |
| Von Euler et al. | β-(3: 4-dihydroxyphenyl) ethylamine (hydroxytyramine) in normal human urine | |
| KR860000865A (ko) | 약제 제형의 제조방법 | |
| DE69634434D1 (de) | Verfahren zur herstellung von di-beta-d-glucopyranosylamin-verbindungen zur regulierung von entzündungsprozessen | |
| NO20035434D0 (no) | Behandling eller profylakse av transplantasjonsavst degree tning av insulinproduserende celler | |
| BR0014042A (pt) | Método e sistema para uso de preferências da pessoa que telefona para direcionar tratamento especial da chamada | |
| SE8701479D0 (sv) | Metod for inneslutning av biologiskt verksamma preparat samt anvendning derav | |
| SE9600046D0 (sv) | New pharmaceutical formulation | |
| WO1997000671A3 (de) | Zusammensetzung zur herstellung feindisperser systeme und verfahren zu ihrer herstellung | |
| IE36563B1 (en) | New diazepine derivatives and processes for their production | |
| JPS5354866A (en) | Method of treating sewege | |
| JPS54126722A (en) | Slow release antibiotic tablet | |
| Mori et al. | Histochemical detection of three dehydrogenase systems in ameloblastoma | |
| JPS5257390A (en) | Immobilized enzyme and method of preparing the same | |
| JPS52151732A (en) | Prophylactic and therapeutic agent against bacterial | |
| KR920013742A (ko) | 트렌치를 이용한 바이폴라 액티브 영역 형성방법 | |
| Dileepan et al. | Effect of Vasoactive Agents on Fatty Acid Metabolism: Inhibition of Lipolysis by Tipropidil in Rat Epididymal Adipose Tissue |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 873133 Country of ref document: ES |